Cambridge startup Kymera Therapeutics just earned $70 million and could get up to $1 billion after signing a four-year collaboration deal with Vertex Pharmaceuticals.

Vertex (Nasdaq: VRTX) has cornered the market for cystic fibrosis, a rare genetic disease that affects a person’s lungs. But the company has recently branched out through its blood disorder collaboration with gene editing startup CRISPR Therapeutics, and it may be expanding its reach further through the deal with Kymera.

Under the…

Boston Biz Journal